Thomas Lund

8PUBLICATIONS
40CO-AUTHORS
Regenerative medicine (incl. stem cells)HaematologyMedical infection agents (incl. prions)Nanotoxicology, health and safetyMental health nursing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 25, 2026
Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma.

|Jun 23, 2026
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

|Feb 09, 2026
Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma.

Kieran Brennan, Katrine F Iversen, Alfonso Blanco-Fernández

|Jun 26, 2025
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

Thomas Lund, Cyrus Khandanpour, Sébastien Anguille

|Apr 01, 2025
Home-Based Daratumumab in Patients With Multiple Myeloma.

Tine Rosenberg, Jannie Kirkegaard, Michael Tveden Gundesen

|Apr 15, 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.

Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted

Pageof 2

Frequent Collaborators

2 joint publications

Marta Diaz-delCastillo

2 joint publications

Michael Tveden Gundesen

2 joint publications

Jannie Kirkegaard

2 joint publications

Jon Thor Asmussen